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Tumor growthProtein folding quality control does not occur randomly in cells, but requires the action of specialized molec-
ular chaperones compartmentalized in subcellular microenvironments and organelles. Fresh experimental
evidence has now linked a mitochondrial-speciﬁc Heat Shock Protein-90 (Hsp90) homolog, Tumor Necrosis
Factor Receptor-Associated Protein-1 (TRAP-1) to pleiotropic signaling circuitries of organelle integrity and
cellular homeostasis. TRAP-1-directed compartmentalized protein folding is broadly exploited in cancer
and neurodegenerative diseases, presenting new opportunities for therapeutic intervention in humans.
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Molecular chaperones of the Hsp90 gene family are considered in-
dispensable regulators of protein folding quality control in virtually
every organism [1]. Their structure–function properties, regulation
by sequential cycles of ATP hydrolysis, and requirement for hosts of
co-chaperones in maintaining the stability, maturation and subcellu-
lar trafﬁcking of disparate client proteins have been the subject of in-
tense interest, and are reviewed elsewhere in this monographic
contribution. There has also been growing appreciation that chaper-
one control of proteostasis is often subverted in human diseases, in-
cluding cancer [2], and may provide therapeutic opportunities [3].
What has also emerged, adding further complexity to this network,
is the role of Hsp90-like chaperones compartmentalized in organelles
and discrete subcellular microenvironments [4]. As specialized resi-
dent chaperones of the endoplasmic reticulum (ER) [5], as well as mi-
tochondria [6], organelle-speciﬁc Hsp90 molecules are being
recognized not only as subcellular orchestrators of protein folding
quality control, but also as hubs for far-reaching signaling pathways
of cellular homeostasis.
Much of our knowledge regarding organelle-speciﬁc chaperoning
comes from the ER-compartmentalized Hsp90-like molecule,
Glucose-Regulated Protein 94 (Grp94) [5]. Recognized for its selectiv-
ity of client protein recognition and association with ER late foldingintermediates, Grp94 functions as a pivotal regulator of ER proteosta-
sis. However, it is now clear that Grp94 also controls Ca2+ balance,
proteotoxic stress response, embryonic development, stem cell main-
tenance, host defense, as well as cell adhesion [7–10]. We also know
that at least some of these pathways are subverted in human diseases,
especially cancer, where increased expression of Grp94 has been
linked to tumor cell proliferation, metastasis and drug resistance [11].
Conversely, our understanding of Hsp90-like molecule(s) local-
ized to mitochondria has long remained more elusive, complicated
by the unique organelle architecture, and the role of chaperones in
both mitochondrial preprotein import and intra-organelle proteolysis
[12]. Fresh experimental evidence has now brought the
mitochondrial-compartmentalized Hsp90-like chaperone, Tumor Ne-
crosis Factor Receptor-Associated Protein 1 (TRAP-1) [6], to the fore-
front of pivotal pathways of mitochondrial integrity, oxidative cell
death, organelle-compartmentalized protein folding, and transcrip-
tional responses to proteotoxic stress. In addition, aberrant deregula-
tion of TRAP-1 function has been noted in cancer and
neurodegenerative disorders, with potential far-reaching conse-
quences for disease progression and therapeutic intervention.2. TRAP-1 structure–function
TRAP-1 was ﬁrst identiﬁed as an Hsp90-like chaperone while
screening for proteins associated with the cytoplasmic domain of
the type 1 Tumor Necrosis Factor Receptor-1 (TNFR1) using the
yeast two-hybrid system [13]. A positive clone bound to theNH2-termi-
nal domain of TNFR-1 in vitro, and was designated TNFR1-Associated
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Hsp90-like protein of ~75 kD, and designated Hsp75, was also identiﬁed
that bound the Retinoblastoma (Rb) protein [14]. Functionally, this
Hsp75 proteinwas implicated in subcellular trafﬁcking of Rb duringmito-
sis, as well as heat shock [14]. Sequence analysis later determined that
TRAP-1 and Hsp75 were identical molecules.
In terms of tissue distribution, an ~2.4 kb TRAP-1 mRNA was orig-
inally detected in normal tissues, but more highly represented in
tumor cell lines [13]. By sequence alignment, a TRAP-1 cDNA showed
34% identity and 60% homology with members of the Hsp90 gene
family [13]. Current annotations in public databases indicate that a
TRAP-1 mRNA of 2225 nucleotides is transcribed from a single locus
on chromosome 16p13 in humans. Transcription from this locus is
heterogeneous, and gives rise to at least 14 independent mRNA spe-
cies, with extensive nucleotide polymorphism. At least 6 TRAP-1 pro-
tein variants (TRAP-1 1–6) are predicted, characterized by different
splicing patterns, amino acid additions, or deletions. Translation of
the main TRAP-1 mRNA generates a precursor protein of 704 amino
acids, containing a putative mitochondrial import sequence of 59
amino acids, which is removed upon organelle import. A mature
TRAP-1 protein of 645 amino acids contains an ATP binding pocket
that conforms to the Bergerat ATP-binding fold found in Hsp90, gyr-
ases and MutL in which ATP binds with an unusual kinked conforma-
tion with the γ-phosphate group oriented towards the NH2 terminus
[15] (Table 1). Sequence analysis suggests that several amino acids in
TRAP-1 may be potential targets for post-translational modiﬁcations,
including acetylation and phosphorylation, whereas the molecule
lacks a COOH-terminus MEEVD sequence, which is characteristic of
cytosolic Hsp90 (Table 1). Structurally, and similar to yeast Hsp90,
TRAP-1 forms a tight homodimer with melting temperature of 55 °C
[16], thus considerably more stable than Grp94, which denatures at
approximately 30 °C. Also different from Grp94, TRAP-1 ATPase activ-
ity is induced by ~200 fold in response to heat shock. Phylogenetic
analysis suggests that TRAP-1 originated from a common ancestor
that also gave rise to cytosolic and ER Hsp90s. However, its divergent
nucleotide and protein features suggest that TRAP-1 may be a more
distant paralogue of this class [17].
Accordingly, there are important functional differences between
TRAP-1 and other Hsp90 molecules (Table 1). For instance, TRAP-1
does not bind co-chaperones, p23 or Hop (p60), and cannot substi-
tute for Hsp90 to enable the progesterone receptor hormone-
binding state, i.e. receptor maturation [6]. Conversely, similar to
Hsp90, TRAP-1 ATPase activity is inhibitable by the small molecule
pocket antagonists, Geldanamycin or radicicol, which have been ex-
tensively used to probe Hsp90's role in protein folding [6] (Table 1).
The ATPase cycle of TRAP-1 has been recently studied in some de-
tail [16]. Differently from Grp94, which remains in an open conﬁgura-
tion upon nucleotide binding, but reminiscent of human Hsp90, ATP
binding shifts TRAP-1 conformation to a predominantly closed conﬁg-
uration, albeit with slower kinetics than Hsp90 [16]. In this context,
TRAP-1 binds nucleotide approximately 10 times tighter than
human or yeast Hsp90. However, ATP binding to TRAP-1 isTable 1
Structured–function comparison between TRAP-1 and Hsp90.
Structure–function properties TRAP-1 Hsp90
Bergerat-type ATP-binding fold Yes Yes
Tight homodimer architecture Yes Yes
Post-translational modiﬁcations
(phosphorylation, acetylation)
Potential Yes
MEEVD sequence
(tetratricopeptide repeat recognition)
No Yes
Binding to co-chaperones (p23, Hop) No Yes
Inhibited by Geldanamycin, radicicol Yes Yes
Mitochondrial localization Yes Yes (only in tumors)insufﬁcient to commit to nucleotide hydrolysis, and is instead fol-
lowed by re-opening of the chaperone conﬁguration, which occurs
faster than the rate of hydrolysis. This has prompted a two-step
model for TRAP-1 ATPase cycle with ATP binding followed by irre-
versible hydrolysis, quantitatively comparable or higher than that of
Hsp90 [16].
Subcellular localization studies conducted with newly produced
antibodies conﬁrmed sequence predictions that TRAP-1 is indeed a
mitochondrial-compartmentalized Hsp90-like chaperone [6,18].
TRAP-1 organelle import requires the predicted NH2-terminal mito-
chondrial localization sequence, and appears evolutionary conserved,
as a putative TRAP-1 homolog in Drosophila was also localized to mi-
tochondria [6]. In terms of sub-organelle topography, immunogold
electron microscopy and biochemical studies suggested that TRAP-1
predominantly accumulates in the mitochondrial matrix [18], with a
fraction that may also distribute to the intermembrane space, as
more recently proposed [19]. In certain tissues, an extramitochondrial
localization of TRAP-1 has also been noted [18], but its potential func-
tion was not further investigated. How an almost exclusive mitochon-
drial localization of TRAP-1 could be reconciled with its potential
association with TNFR1 [13], or Rb [14] has so far remained unclear.
3. TRAP-1 cytoprotection against oxidative stress and mitochon-
drial cell death
The ﬁrst function assigned to TRAP-1 was protection against mito-
chondrial apoptosis (Fig. 1). There is now a general consensus that
mammalian cells utilize two main circuitries to commit suicide by
programmed cell death: an extrinsic pathway centered on the recog-
nition and signaling properties of death receptor molecules at the cell
surface [20], and an intrinsic or mitochondrial pathway, centered on
the sudden induction of organelle dysfunction by various apoptotic
stimuli, and culminating with the release of apoptogenic proteins,
most notably, cytochrome c, in the cytosol [21]. There is extensive
functional crosstalk between these two pathways, and both converge
on the activation of a caspase cascade, ultimately responsible for dis-
mantling the cell's architecture [22]. In studying the anti-tumorigenic
properties of a non-ATP competitive tyrosine kinase inhibitor, the
natural compound β-hydroxyisovalerylshikonin (β-HIVS), Masuda
and collaborators found that tumor cells treated with this agent or a
DNA-damaging chemotherapeutic, VP-16, exhibited decreased ex-
pression of TRAP-1, which was associated with enhanced mitochon-
drial apoptosis [23]. Silencing of TRAP-1 by small interfering RNA
(siRNA) reproduced the same phenotype, pointing to a protective
role of this chaperone on mitochondrial integrity [23].
A similar conclusion was reached in independent studies looking at
cell death pathways activated during innate immunity, a host defense
mechanism against viral infection and, potentially, oncogenic transfor-
mation. One of the lesser studied mediators of this response is Gran-
zyme M, a serine protease stored in granules of effector cell
populations, and released in the extracellular environment during tar-
get cell killing [24]. Mechanistically, GranzymeM acts on themitochon-
dria, inducing loss of transmembrane potential, swelling of the matrix,
generation of reactive oxygen species (ROS), and discharge of cyto-
chrome c [25]. It turns out that GranzymeM cleavage of TRAP-1 within
mitochondria contributed to this cell death response. This proteolytic
event caused loss of TRAP-1 ATPase activity, associated with increased
production of ROS, cytochrome c release and enhanced apoptosis [25].
Other evidence suggests that TRAP-1 cytoprotection may be im-
portant to help cells cope with oxidative stress, and thus thwart the
ensuing ROS-mediated apoptosis (Fig. 1). Accordingly, changes in
TRAP-1 levels induced by anti-tumor agents, β-HIVS or VP-16 were
prevented by a ROS scavenger [23], and treatment of normal hepato-
cytes with the iron chelator, deferoxamine decreased TRAP-1 expres-
sion, while concomitantly elevating ROS production in these cells
[26]. Mirroring these results, stable expression of TRAP-1 attenuated
Fig. 1. TRAP-1 cytoprotection. The differential expression of TRAP-1 in cancer, as opposed to normal tissues has been implicated in inhibition of mitochondrial apoptosis, suppres-
sion of ROS production, and acquisition of resistance to standard chemotherapeutics. Effective cytoprotection under these conditions may require TRAP-1 phosphorylation by the
mitochondrial-localized kinase, PINK1, which associates with TRAP-1, in vivo. The Ca2+ binding protein, Sorcin is also a TRAP-1-associated molecule, which opposes TRAP-1 deg-
radation within the organelle.
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ance of markers of oxidative stress [26]. The idea of TRAP-1 as a
stress-responsive cytoprotective chaperone, whether following onco-
gene expression, ROS production or DNA damage, gained further sup-
port from independent studies. Accordingly, microarray analyses
identiﬁed TRAP-1 as one of the target genes upregulated by the
Myc oncogene [27], and tumor cells rendered chronically resistant
to cisplatin or other chemotherapeutic agents consistently showed
an increase in TRAP-1 expression levels [28]. Functionally, these
TRAP-1-positive cells become resistant to oxidative stress (H2O2)-
induced apoptosis, with decreased expression of oxidative markers,
and reduced activation of apoptotic and non-apoptotic pathways
[29]. How modulation of TRAP-1 levels is controlled under condi-
tions of cellular stress is still largely unexplored. Although some of
these mechanisms are likely transcriptional, very little information
is available concerning the requirements of TRAP-1 gene expression
under basal or stress conditions.
Butwhat are the regulators of TRAP-1 in buffering ROS production in
mitochondria and opposing oxidative cell death? A clue to this question
came from studies looking at neuronal cell death in neurodegenerative
diseases, in particular Parkinson's disease (PD) [30]. It had long been ap-
preciated that selective loss of dopaminergic neurons in the substantia
grigia is a hallmark of PD [30]. There is also evidence from postmortem
analyses of primary human specimens ofmitochondrial defects in these
patients, especially deﬁciencies of complex I [31]. One of the keymolec-
ular players in this pathway was uncovered in genetic studies of pa-
tients with recessively inherited PD, which identiﬁed hosts of
inactivating mutations in a mitochondrial-localized serine–threonine
kinase, designated PTEN-Induced Putative Kinase, or PINK1 [32]. Similar
mutations were later found in late-onset PD patients, suggesting that
deregulation of PINK1 function due to acquiredmutation(s) could func-
tion as a disease-driver in neurodegeneration. Functionally, PINK1 had
been linked to an evolutionary-conserved anti-apoptotic pathway
[33], but the requirements of this response, and the potential target sub-
strate(s) of its kinase activity, if at all involved in cytoprotection, had not
been identiﬁed. Against this backdrop, Pridgeon and colleagues found
that PINK1 cytoprotection required TRAP-1, and, in fact, depended on
an active mechanism of PINK1 phosphorylation of TRAP-1 within mito-
chondria, in vivo [19]. In turn, PINK1-phosphorylated TRAP-1 opposed
mitochondrial dysfunction and suppressed oxidative stress-induced ap-
optosis [19] (Fig. 1). Importantly, variants of PINK1 that carried the inac-
tivating mutations found in PD patients were unable to phosphorylateTRAP-1, and to reverse apoptosis [19]. On this basis, PINK1 phosphory-
lation seems to provide a necessary step to enable TRAP-1 cytoprotec-
tion and preserve mitochondrial integrity, at least in model of
neuronal cells, but the identity of potential downstream target(s) of
TRAP-1 had remained elusive [19], a point that came into better focus
from results obtained in tumor cells.
4. Exploitation of TRAP-1 cytoprotection in cancer
Although there had been suggestions that TRAP-1 cytoprotection
was somehow exploited in cancer, the actual distribution of this
chaperone in normal versus malignant tissues in vivo had not been
formally investigated. Recent studies addressed this question, and
found that TRAP-1 levels were consistently elevated in primary
human tumor specimens, while present at very low levels, and some-
times undetectable in the corresponding normal tissues, in vivo [34].
In prostate cancer, TRAP-1 differential expression proved an attrac-
tive biomarker of disease, being abundantly represented in prostatic
intraepithelial neoplasia (PIN), all Gleason grade primary tumors,
and metastatic disease to bone and lymph nodes, while largely unde-
tectable in normal prostatic epithelium or benign prostatic hyperpla-
sia [35]. Unexpectedly, these studies also identiﬁed a previously
unrecognized pool of Hsp90 localized to mitochondria [34]. Similar
to the data with TRAP-1, also the pool of mitochondrial Hsp90 was
differentially expressed in tumors, in vivo, while undetectable in the
corresponding normal tissues [34].
Additional studies aimed at identifying potential molecular part-
ners of mitochondrial Hsp90 and TRAP-1 in tumor cells [34]. Here,
biochemical evidence demonstrated that both of these two chaper-
ones physically associated with cyclophilin D (CypD), a matrix pepti-
dyl prolyl isomerase (PPI), which is a physical component of the
organelle permeability transition pore (PTP) [34]. There is a general
consensus that opening of the mitochondrial PTP is a key molecular
prerequisite for induction of mitochondrial apoptosis [21]. Biochemi-
cally, this process, also called mitochondrial permeability transition,
comprises a cascade of events, which include sudden increase in mi-
tochondrial permeability to solutes, swelling of the matrix, dissipa-
tion of transmembrane potential, remodeling of the cristae, and
ultimately rupture of the outer membrane with release of apopto-
genic cytochrome c into the cytosol [21].
Despite the broad acceptance of this model, the actual molecular
composition of the PTP is still a matter of debate [36], as proteins
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channel (VDAC) [37], and the adenine nucleotide translocator (ANT)
[38], do not seem to participate in apoptosis, at least based on the
negative phenotype of knockout studies. There is also uncertainty as
to whether the model of a rigid mitochondrial PTP faithfully recapit-
ulates how organelle cell death is actually initiated [21]. In fact, a
more dynamic model has been proposed, in which aggregated
and/or misfolded proteins cluster at the outer mitochondrial mem-
brane as a result of stress conditions, including Ca2+ imbalance, and
have the ability to conduct solutes, thus initiating permeability tran-
sition [39] (Fig. 2). These controversies aside, knockout studies have
unambiguously demonstrated that CypD is indeed required for PTP
opening and oxidative stress-induced apoptosis [40,41]. This concept
has also been validated in animal studies, as deletion of CypD and ab-
rogation of its pro-apoptotic properties protected against aberrantly
increased cell death in various disease models [42], including neuro-
degeneration [43], in vivo. Against this backdrop, a functional interac-
tion between TRAP-1 and CypD [34] ﬁts well with the ability of this
chaperone to modulate oxidative stress responses, and antagonize
ROS-mediated cellular damage [19,23,25]. Conceptually, this ﬁts
well also with a proposed CypD regulation of mitochondrial perme-
ability transition [21] mediated by protein misfolding at the outer
membrane (Fig. 2), a model that postulates a critical role of
chaperone-mediated protein (re)folding in antagonizing cell death
[39].
However, available evidence is still insufﬁcient to conclude that
CypD is the ﬁrst mitochondrial client protein of TRAP-1, refolded in
a closed PTP conﬁguration by the chaperone ATPase activity. For in-
stance, the structure–function relationship of a TRAP-1-CypD com-
plex has not been characterized, so that it is unclear whether this
recognition conforms to the paradigm of an Hsp90-client protein in-
teraction. On the other hand, recent studies were carried out to ad-
dress the requirement of TRAP-1 ATPase activity in regulating
CypD-dependent mitochondrial permeability transition [21]. Surpris-
ingly, despite the wealth of structurally diverse small molecule Hsp90
antagonists in (pre)clinical development [3], none of these com-
pounds was shown to have the ability to accumulate in mitochondria,
and trigger permeability transition [44]. Conversely, a synthetic pep-
tidomimetic inhibitor of Hsp90 ATPase activity, Shepherdin [45],
which was structurally modeled on the Hsp90–survivin binding in-
terface [46], readily accumulated in mitochondria [34]. It is stillFig. 2. Regulation of mitochondrial permeability pore opening by an organelle-speciﬁc cha
with CypD, and mediate ATPase dependent closing of the permeability transition pore (PTP
CypD, VDAC and ANT (left), and a dynamic PTP (right), characterized by the pore-forming
tochondrial membrane under conditions of stress. VDAC, voltage-dependent anion channelunclear what enables Shepherdin to penetrate inside mitochondria,
but domain swapping experiments suggested that this property was
likely mediated by the highly positively charged Antennapedia cell
penetrating moiety placed at Shepherdin's NH2-terminus, which
was also responsible for its distribution to all submitochondrial com-
partments [34]. Functionally, Shepherdin inhibition of TRAP-1, and
likely also mitochondrial Hsp90 ATPase activity triggered rapid col-
lapse of mitochondrial integrity in tumor cells [34], with loss of trans-
membrane potential, release of cytochrome c, caspase activation and
extensive cell death [34,45]. Importantly, this cell death pathway re-
quired CypD PPIase function [34,45], suggesting that opening of the
PTP was an obligatory molecular prerequisite in cell death induction
[21]. Conversely, Shepherdin did not affect normal cells [34,45], in
keeping with the low level of TRAP-1 and mitochondrial Hsp90 in or-
ganelles of normal tissues [34].
Altogether, these data support a model in which TRAP-1 antago-
nizes CypD pore-forming properties, potentially by protein (re)fold-
ing [39], and blunts the main cell death pathway maintained by
CypD [21], namely oxidative apoptosis [40,41] (Figs. 1, 2). In cancer,
such adaptive response may be important to endow tumor cells
with the ability to thrive in unfavorable environments, i.e. rich in
ROS. This is consistentwith the high levels of TRAP-1 (as well as ofmito-
chondrial Hsp90) found in various types of cancer, in vivo [34], suggest-
ing that this pathway is not only broadly exploited for disease
maintenance, but may also favor the acquisition of additional malignant
traits, in vivo. Accordingly, over-expressed TRAP-1 in a fraction of colo-
rectal cancer cases has been associatedwithmulti-drug resistance via in-
hibition of mitochondrial apoptosis [28], and genome-wide association
studies also in colorectal cancer identiﬁed a 72-gene signature, compris-
ing TRAP-1, which correlated with drug resistance and disease progres-
sion [47]. Mechanistically, recent proteomics data in non-tumor cell
types identiﬁed TRAP-1 as a bona ﬁde hypoxia-regulated gene, whose
expression is signiﬁcantly increased under conditions of low oxygen ten-
sion, even though the genetic requirements of this response, whether
transcriptional or post-transcriptional, have not been further elucidated
[48].
Although CypD [34], and PINK1 [19], are pivotal for TRAP-1 cytopro-
tection, the existence of additional regulator(s) of this pathway has
been intensely pursued. Using a proteomics approach, a novel TRAP-
1-interacting molecule was recently identiﬁed as a mitochondrial-
localized, lower molecular weight isoform of the Ca2+ binding protein,perone network. Molecular chaperones Hsp90, Hsp60 and TRAP-1 physically associate
). Two potential models of PTP regulation are presented: an organized PTP comprising
properties of clusters of misfolded and aggregated proteins generated at the outer mi-
; ANT, adenine nucleotide translocator; CypD, cyclophilin D; C, cytochrome c.
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gene family of Ca2+-dependent regulators of protein interactions, and
its binding to TRAP-1 has been implicated in increasing the stability of
the chaperone presumably against proteolytic degradation in mito-
chondria [49]. Functionally, this was also associated with inhibition of
apoptosis and development of a multi-drug resistant phenotype in
colon cancer cells [49] (Fig. 1). In an independent study, a biochemical
approach of size exclusion chromatography of normal or tumor mito-
chondrial extracts identiﬁed the mitochondrial-localized chaperonin,
Hsp60 as an additional CypD-associated molecule, in vivo [50]. Experi-
ments with recombinant proteins conﬁrmed that Hsp60 bound CypD
directly, and that this interaction was also required to antagonize
CypD-dependent mitochondrial apoptosis [50] (Fig. 2). Similar to the
paradigm of other mitochondrial chaperones that interact with CypD,
Hsp60 was also differentially over-expressed in organelles of tumor
cells, compared to normal tissues, where no biochemical interaction be-
tween “normal” Hsp60 and CypD was demonstrated [34]. In terms of
disease relevance, Hsp60 inhibition of CypD-mediated permeability
transition was important for tumor maintenance, as stable silencing of
Hsp60 in model glioblastoma cell types inhibited intracranial tumor
growth and prolonged animal survival, in vivo [34].
5. Targeting TRAP-1 for subcellularly-compartmentalized cancer
therapeutics
Taken together, the data above suggest the existence of not just
one molecule, but of a network of mitochondrial-localized molecular
chaperones, potentially regulated by post-translational modiﬁcations,
i.e. phosphorylation [19], and stabilized by Ca2+ sensing proteins [49]
(Fig. 1), which antagonizes CypD-dependent pore-forming properties
[21], and oxidative cell death [40,41] in tumors, potentially via
ATPase-directed protein (re)folding (Fig. 2). Because of its nearly
ubiquitous differential expression in cancer, as opposed to normal tis-
sues, these properties may make this mitochondrial chaperone net-
work a potentially attractive target for cancer therapy [3].
Proof-of-concept results obtained with Shepherdin supported this
model [34,45], and reiterated the feasibility of selective targeting of
Hsp90 chaperones speciﬁcally in specialized subcellular compartments.Fig. 3. TRAP-1 control of cell survival and stress response. Inhibition of TRAP-1 and mitoch
results in activation of apoptosis, induction of UPR with transcriptional upregulation of a stTo further test this concept, and circumvent the limitations of peptido-
mimetics in drug development, a new class of small molecule Hsp90 in-
hibitors selectively engineered to accumulate in mitochondria was
recently synthesized. These compounds, designated as Gamitrinibs
(GA mitochondrial matrix inhibitors) have a combinatorial design, in
which the ATPase inhibitory component of 17-allylaminogeldanamycin
(17-AAG) is fused through a linker region to a “mitochondriotropic”moi-
ety, provided by either 1–4 tandem repeats of guanidinium or, alterna-
tively, triphenylphosphonium [44].
Accordingly, Gamitrinibs readily accumulated in mitochondria of
normal or tumor cells, and inhibited the ATPase activity of TRAP-1
(and likely of mitochondrial Hsp90), inducing collapse of mitochon-
drial integrity, and all the biochemical hallmarks of PTP opening
[44] (Fig. 3). When tested in a preclinical model of prostate cancer,
Gamitrinibs indistinguishably induced apoptosis of androgen-
dependent or -independent prostate cancer cells [35], and killed che-
moresistant prostate cancer cells that over-expressed the P-
glycoprotein transporter, independently of pro- or anti-apoptotic
Bcl-2 proteins, as general orchestrators of mitochondrial cell death
[51]. Conversely, Gamitrinibs had no effect on normal cell types, in-
cluding normal prostatic epithelium [35,51]. Consistent with a selec-
tive, “mitochondriotropic” mechanism of action, Gamitrinibs did not
inhibit the chaperone activity of cytosolic Hsp90, with no difference
in the level of expression of client proteins, Akt or Chk1, or of the
Heat Shock Factor (Hsf)-regulated chaperone, Hsp70 [44,51]. When
analyzed in xenograft or genetic mouse models of prostate cancer,
Gamitrinibs had encouraging anticancer activity and tolerability, inhi-
biting localized or bone metastatic disease, with no overt organ or
systemic toxicity, in vivo [51,52].
Altogether, the results obtained with Shepherdin [34,45], and, now,
with Gamitrinibs [51,52], argue that TRAP-1 ATPase activity is required
to maintain tumor cell viability, and that genetically heterogeneous tu-
mors may become “addicted” to this survival mechanism (Fig. 3). But is
the effect of these agents truly related to changes in the protein folding
environment inmitochondria? To begin probing this question,more re-
cent experiments were carried out with sub-optimal concentrations of
Gamitrinibs, enough to alter ATPase-directed protein folding within
the organelle's conﬁnes, but insufﬁcient to trigger irreversible collapseondrial Hsp90 ATPase activity by subcellularly targeted small molecules, Gamitrinibs,
ress response gene signature, and compensatory autophagy.
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ditions, the Gamitrinib variant containing triphenylphosphonium as
mitochondriotropic moiety [44] initiated a complex signaling pathway
in tumor cells, characterized by accumulation of unfolded, i.e. insoluble
proteins in mitochondria, and expression of organelle stress markers
[53]. These are features of an unfolded protein response (UPR), a cellu-
lar and transcriptional program that has been well-characterized in re-
sponse to ER damage [54,55], but far less deﬁned when it comes to
mitochondria [12] (Fig. 3).
Reminiscent of an ER UPR [54,55], tumor cells treated with low
dose Gamitrinib also underwent dramatic changes in gene expression
proﬁle, with upregulation of stress response transcription factor,
CCAAT Enhancer Binding Protein (C/EBPβ), and its dimerization part-
ner C/EBP homology protein, CHOP, and increased expression of sev-
eral molecular chaperones, including Hsp70 [53] (Fig. 3). A third
phenotype observed under these conditions was a dramatic activa-
tion of autophagy [53] (Fig. 3), a process of self-digestion of subcellu-
lar organelles that aims at maintaining cellular energy levels under
stress conditions [56]. The role of autophagy in cancer is still debated,
as to whether this functions as a cell death mechanism, a cell survival
phenotype, or both [57]. In the case of Gamitrinib, activation of autop-
hagy was clearly a compensatory survival mechanism, as its genetic
or pharmacologic inhibitors converted non-cytotoxic concentrations
of Gamitrinib into effective tumor cell killing regimens [53].
One of the transcriptional networks thatwas shut down by low dose
Gamitrinib was NFκB, which resulted in a concomitant loss of several
NFκB downstream target genes [53]. There has been intense interest
in NFκB as a survival pathway almost ubiquitously exploited in tumors,
and the possibility that targeting its function may enhance the efﬁcacy
of anticancer therapies has been intensely pursued [58]. Accordingly,
combining low, non-cytotoxic concentrations of Gamitrinib with a cell
death inducer normally antagonized byNFκB, i.e. TumorNecrosis Factor
Apoptosis-Inducing Ligand (TRAIL) [59], dramatically enhanced anti-
cancer activity, killing disparate tumor cell types, and inhibiting intra-
cranial glioblastoma growth in mice, with no detectable toxicity, in
vivo [53]. These ﬁndings are consistent with other data linking changes
in TRAP-1 expression tomodulation of gene transcription pursued in re-
cent molecular proﬁling studies [60]. Here, tumor cell types that were
differentially induced or silenced for TRAP-1 expression exhibited upre-
gulation of proliferation-associated genes, or regulators of cell motility
and metastatic spread, respectively [60].
6. Outstanding questions and future directions
Originally considered a somewhat elusive member of the Hsp90
gene family, TRAP-1 has now emerged as a novel and potentially pivotal
regulator ofmitochondrial integrity. Its link to the control of apoptosis is
now fairly established, especially in the context of oxidative stress, and
some of its key molecular partners in this pathway, for instance CypD
[34], and PINK1 [19], have been identiﬁed. It is also clear that the
TRAP-1 pathway of cytoprotection is subverted in human diseases,
most notably, cancer and neurodegeneration. Despite the wealth of
new data, many open questions still remain. For instance, targeting
TRAP-1 expression or function triggers amitochondrial UPR that global-
ly reprograms the cellular transcriptome [53,60]. But how are potential
signals of proteotoxic stress generated within mitochondria relayed to
the nucleus to control gene expression? The answer to this question is
presently unknown, but a number of scenarios can be envisioned, in-
cluding production of second messengers, for instance Ca2+ imbalance
[61], or soluble peptides generated from mitochondrial proteotoxicity
[62], which can ultimately affect nuclear gene expression under these
conditions. In a fanciful scenario, it is also possible that proteotoxic sig-
nals originating from mitochondria may spread to activate the potent,
multi-pronged ER-stress sensing machinery [54,55] to further amplify
nuclear gene expression. Such concept of an inter-organelle signaling
network has been proposed earlier [63], and this putative subcellularcooperation may be well suited to generalize the cellular response to
stress. After all, mitochondria and ER share extensive areas of physical
contact [64], populated by diverse classes of chaperones ideally posi-
tioned to process proteotoxic stress signals, andmaximize compensato-
ry gene expression programs [61].
Second, targeting TRAP-1 triggers massive activation of autophagy
as a compensatory response likely to eliminate damaged mitochon-
dria, and more recent data have shown that the TRAP-1-
phosphorylating kinase, PINK1 [19], is also an indispensable regulator
of this process [65]. But how is autophagy activated after TRAP-1 tar-
geting? We know that ER stress is linked to activation of autophagy,
and that this process is also important for cell survival [66], but the
circuitries linking TRAP-1 ATPase activity, control of mitochondrial
protein folding and stimulation of autophagy are not known.
And, ﬁnally, is TRAP-1 as good as a cancer therapeutic target as
some of the preclinical data with Shepherdin [45], or Gamitrinibs
[44,51,52] may suggest? Despite the intense interest in exploiting
the nodal properties Hsp90 for cancer therapeutics [2], the results of
clinical trials with structurally diverse small molecule Hsp90 inhibi-
tors have not been particularly overwhelming [3]. Can it be that this
is because the compounds currently in the clinic do not penetrate mi-
tochondria [44], and, therefore, leave unscathed the pivotal survival
role of compartmentalized Hsp90 and TRAP-1? And, if so, does this
mean that we have to contemplate the additional concept of “subcel-
lular targeting” in drug development, as only ATPase antagonists di-
rected to subcellular compartments [67] can unlock the potential of
molecular chaperones as universal drug targets, and produce durable
responses in cancer patients [68]? Given the fast pace of research in
this exciting ﬁeld of investigation, the answers to some of these ques-
tions will undoubtedly be forthcoming.
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